Translating research into practice: The role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation

Medical Care

Volumn 50, Issue 8, 2012, Pages 737-748

  Carpenter, William R ^a,b   Meyer, Anne Marie ^b   Wu, Yang ^b   Qaqish, Bahjat ^a   Sanoff, Hanna K ^c   Goldberg, Richard M ^d   Weiner, Bryan J ^a,b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

colon cancer; diffusion of innovation; organization and administration; provider based research networks; translational research

Indexed keywords

FLUOROURACIL; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER STAGING; COLON CANCER; EVIDENCE BASED PRACTICE; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSLATIONAL RESEARCH;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CHEMORADIOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DIFFUSION OF INNOVATION; FLUOROURACIL; HUMANS; MEDICARE; ORGANOPLATINUM COMPOUNDS; PYRIDINES; RETROSPECTIVE STUDIES; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES;

EID: 84863826171     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31824ebe13     Document Type: Article

References (44)

1. Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality. JAMA. 1998;280:1000-1005.
2. Institute of Medicine. Ensuring Quality Cancer Care. Washington, DC: National Academies Press; 1999.
3. Institute of Medicine. Crossing the Quality Chasm: a New Health System for the 21st Century. Washington DC: National Academies Press; 2001.
4. Institute of Medicine. Bridging the Gap Between Practice and Research. Washington DC: National Academies Press; 1998.
5. Balas E. Information technology and physician decision support. Program and abstracts of Accelerating Quality Improvement in Health Care: Strategies to Speed the Diffusion of Evidence-based Innovations, sponsored by National Committee for Quality Health Care. Washington DC January 27-28, 2003.
6. Westfall JM, Mold J, Fagnan L. Practice-based research-"blue highways" on the NIH roadmap. JAMA. 2007;297:403-406. (Pubitemid 46155803)
7. Mariotto A, Feuer EJ, Harlan LC, et al. Trends in use of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst. 2002;94:1626-1634. (Pubitemid 35378728)
8. Zerhouni E. The NIH Roadmap. Science. 2003;302:63-72.
9. Green LA, Fryer GE Jr., Yawn BP, et al. The ecology of medical care revisited. N Engl J Med. 2001;344:2021-2025. (Pubitemid 32568159)
10. Carpenter WR, Weiner BJ, Provider-based Research Networks (PBRNs). Encyclopedia of Health Services Research. SAGE Publications; 2009.
11. Lanier D. Practice-based research networks: laboratories for improving colorectal cancer screening in primary care practice. Med Care. 2008; 46(9 suppl 1):S147-S152.
12. Sales A, Smith J, Curran G, et al. Models, strategies, and tools. Theory in implementing evidence-based findings into health care practice. J Gen Intern Med. 2006;21(suppl 2):S43-S49.
13. Warnecke RB, Johnson TP, Kaluzny AD, et al. The community clinical oncology program: its effect on clinical practice. Jt Comm J Qual Improv. 1995;21:336-339.
14. Laliberte L, Fennell ML, Papandonatos G. The relationship of membership in research networks to compliance with treatment guidelines for early-stage breast cancer. Med Care. 2005;43:471-479. (Pubitemid 40694608)
15. Carpenter WR, Reeder-Hayes K, Bainbridge J, et al. The role of organizational affiliations and research networks in the diffusion of breast cancer treatment innovation. Med Care. 2011;49:172-179.
16. American Cancer Society. Cancer Facts and Figures. 2010. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-026238.pdf. Accessed January 15, 2011.
17. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444-1450.
18. Sanoff HK, Carpenter WR, Martin CF, et al. Comparative effectiveness of oxaliplatin Vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst. 2012;104:211-227.
19. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracilbased adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22:1797-1806. (Pubitemid 41095169)
20. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351. (Pubitemid 38702845)
21. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198-2204. (Pubitemid 46954643)
22. Minasian LM, Carpenter WR, Weiner BJ, et al. Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program. Cancer. 2010;116(19):4440-4449.
23. National Cancer Institute. The NCI Strategic Plan for Leading the Nation To Eliminate the Suffering and Death Due to Cancer. Rockville, MD: National Cancer Institute Available at: http://strategicplan.nci. nih.gov/pdf/nci-2007
24. Hewitt M, Simone J. Enhancing Data Systems to Improve the Quality of Care. Washington DC: National Academy Press; 2000.
25. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40(8 suppl): IV-3-18.
26. Altekruse S, Kosary C, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010.
27. Mack CD, Carpenter W, Meyer AM, et al. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults. Cancer. 2011. [Epub ahead of print].
28. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10:37-48. (Pubitemid 29014427)
29. Klabunde CN, Legler JM, Warren JL, et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17: 584-590. (Pubitemid 47096709)
30. American College of Surgeons Commission on Cancer. Commission on Cancer: about the CoC. 2010. Available at: http://www.facs.org/cancer/coc/whatis.html. Accessed June 1, 2010.
31. Reeder-Hayes KE, Bainbridge J, Meyer AM, et al. Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer. Breast Cancer Res Treat. 2011;128:863-871.
32. National Cancer Institute. Report of the Operational Efficiency Working Group Clinical Trials of the and Translational Research Advisory Committee. Rockville, MD: NCI; 2010. Available at: http://ccct. cancer.gov/files/OEWG- Report.pdf. Accessed July 15, 2011.
33. American Society of Clinical Oncology. QOPI: The Quality Oncology Practice Initiative. Available at: http://qopi.asco.org/. Accessed August 28, 2011.
34. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091-1097.
35. Rothman K, Greenland S, Lash T. Modern Epidemiology. Philadelphia: Lippincott Williams & Wilkins; 2008.
36. Goldman DP, Berry SH, McCabe MS, et al. Incremental treatment costs in national cancer institute-sponsored clinical trials. JAMA. 2003;289: 2970-2977. (Pubitemid 37430099)
37. Ault A. Who should subsidize NCI clinical trials? Nat Med. 1998;4: 992. (Pubitemid 28417318)
38. Emanuel EJ, Schnipper LE, Kamin DY, et al. The costs of conducting clinical research. J Clin Oncol. 2003;21:4145-4150. (Pubitemid 46606182)
39. McBride G. More states mandate coverage of clinical trial costs, but does it make a difference? J Natl Cancer Inst. 2003;95: 1268-1269. (Pubitemid 37160853)
40. Gross CP, Wong N, Dubin JA, et al. Enrollment of older persons in cancer trials after the medicare reimbursement policy change. Arch Intern Med. 2005;165:1514-1520. (Pubitemid 41058032)
41. Martel CL, Li Y, Beckett L, et al. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004;10:294-300. (Pubitemid 44403467)
42. Berwick DM. Measuring physicians' quality and performance: adrift on Lake Wobegon. JAMA. 2009;302:2485-2486.
43. Rosenthal MB. Beyond pay for performance-emerging models of provider-payment reform. N Engl J Med. 2008;359:1197-1200.
44. Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington DC: National Academics Press; 2010.